
Gordon Hill MD
Addiction Medicine
Internist and addiction medicine physician
Join to View Full Profile
.New Haven, CT 06513
Dr. Hill is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am an internist and addiction medicine physician dedicated to providing compassionate, comprehensive primary care to all individuals, including those with substance use disorders. I received advanced training in addiction medicine from the addiction medicine fellowship at Yale University and residency training in internal medicine at Temple University Hospital, a national epicenter for opioid use disorder. I completed medical school and received a masters of science from Drexel University College of Medicine, where I was inducted into the Alpha Omega Alpha and Gold Humanism honor societies.
My career path includes five years of behavioral neuroscience and clinical research, I combine this experience with established motivational interviewing techniques in my partnership with patients to build lasting behavioral treatment strategies. I also leverage these skills to interpret new evidence and incorporate the most advanced, evidence-based treatments available into my practice.
Education & Training
- Yale-New Haven Medical Center (Primary Care)Fellowship, Addiction Medicine, 2023 - 2024
- Temple University HospitalResidency, Internal Medicine, 2020 - 2023
- Drexel University College of MedicineClass of 2020
Certifications & Licensure
- PA State Medical License 2025 - 2026
- CT State Medical License 2023 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Preventive Medicine Addiction Medicine
Awards, Honors, & Recognition
- Alpha Omega Alpha 2020
- Gold Humanism Honor Society 2020
Clinical Trials
- EXHIT ENTRE Comparative Effectiveness Trial Start of enrollment: 2021 Aug 09
Publications & Presentations
PubMed
- Treatment of alcohol use disorder in patients with liver disease.Gordon S Hill, Shawn M Cohen, Melissa B Weimer
Clinical Liver Disease. 2024-06-05 - 7 citationsThe lipid raft-dwelling protein US9 can be manipulated to target APP compartmentalization, APP processing, and neurodegenerative disease pathogenesis.Renato Brandimarti, Gordon S. Hill, Jonathan D. Geiger, Olimpia Meucci
Scientific Reports. 2017-11-08
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: